Comparative Pharmacology
Head-to-head clinical analysis: DEFEROXAMINE MESYLATE versus EXJADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFEROXAMINE MESYLATE versus EXJADE.
DEFEROXAMINE MESYLATE vs EXJADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferoxamine chelates iron by forming a stable complex (ferrioxamine) that is excreted renally, preventing iron from catalyzing free radical formation and reducing tissue damage.
Deferasirox is an oral iron chelator that binds iron with high affinity in a 2:1 ratio. It promotes excretion of iron primarily in the feces via bile, reducing total body iron stores.
For acute iron intoxication: 1 g intramuscularly initially, then 0.5 g every 4 hours for 2 doses, then 0.5 g every 4-12 hours up to a maximum of 6 g/day. For chronic iron overload: 20-40 mg/kg/day subcutaneously over 8-12 hours via infusion pump, or 1-2 g intravenously over 8-24 hours.
20-40 mg/kg orally once daily, titrated based on serum ferritin trends, maximum 40 mg/kg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours for the parent drug after IM or IV administration. The half-life of ferrioxamine is about 6 hours. Clinical context: repeated dosing may be needed for sustained chelation.
Terminal elimination half-life is 8–16 hours, supporting once-daily dosing.
Primarily renal; within 24 hours, approximately 50% of an intramuscular dose is excreted as unchanged drug and 20% as ferrioxamine (the iron chelate). Biliary excretion is minor (<10%).
Primarily fecal (84% of total clearance), with ~8% renal (as unchanged drug and metabolites).
Category A/B
Category C
Iron Chelator
Iron Chelator